SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $5.66, for a total value of $28,300.00. Following the completion of the sale, the insider owned 223,387 shares of the company’s stock, valued at approximately $1,264,370.42. This trade represents a 2.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH traded down $0.08 during trading on Tuesday, reaching $5.57. The company had a trading volume of 154,943 shares, compared to its average volume of 201,098. SOPHiA GENETICS SA has a 52 week low of $2.92 and a 52 week high of $6.77. The stock has a market cap of $467.30 million, a PE ratio of -10.71 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The business’s 50 day moving average price is $5.40 and its 200-day moving average price is $5.08.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. Analysts expect that SOPHiA GENETICS SA will post -0.58 earnings per share for the current year.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS during the 2nd quarter worth $567,000. Royal Bank of Canada lifted its stake in shares of SOPHiA GENETICS by 3,130.2% in the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the period. Sei Investments Co. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $1,772,000. Principal Financial Group Inc. boosted its position in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after purchasing an additional 9,800 shares during the last quarter. Finally, Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS in the 1st quarter worth $2,157,000. 31.59% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

SOPH has been the subject of several research reports. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, HC Wainwright began coverage on SOPHiA GENETICS in a research report on Monday, July 20th. They issued a “buy” rating and a $12.00 price objective for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $9.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.